CXCL12 and colorectal carcinoma: The use of anti-VEGF antibodies in CRC upregulated CXCL12/CXCR4 signaling between cancer cells and Ly6low monocytes, increasing the latter population and thus generating an immunosuppressive environment and increasing the possibility of therapeutic failure [225].